New therapies for hepatitis C

Editorial

Apurva A Modi et al. Hepatology. 2007 Sep.

. 2007 Sep;46(3):615-7.

doi: 10.1002/hep.21892.

No abstract available

Comment on

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Kieffer TL, et al. Hepatology. 2007 Sep;46(3):631-9. doi: 10.1002/hep.21781. Hepatology. 2007. PMID: 17680654 Clinical Trial.
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Forestier N, et al. Hepatology. 2007 Sep;46(3):640-8. doi: 10.1002/hep.21774. Hepatology. 2007. PMID: 17879366 Clinical Trial.